Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
81.6 EUR | -0.49% | +1.25% | +2.53% |
04-02 | Bernstein starts AstraZeneca at 'outperform' | AN |
02-22 | Transcript : Kerry Group plc Presents at 2024 Consumer Analyst Group of New York Conference, Feb-22-2024 10:00 AM |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.53% | 15.03B | - | ||
-4.87% | 265B | A- | ||
-0.83% | 96.62B | C+ | ||
+4.52% | 46.98B | C+ | ||
+7.81% | 39.65B | B- | ||
0.00% | 40.34B | B- | ||
+3.23% | 39.3B | B- | ||
-15.97% | 30.45B | B- | ||
-5.77% | 29.01B | A | ||
+12.89% | 24.9B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- KRZ Stock
- KYGA Stock
- Ratings Kerry Group plc